Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Publication | Open Access

DOI Full Paper Access

390

Citations

References

2017

Year

Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, B. Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,

The Lancet

Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicineRheumatic DiseasesClinical TrialsNecrosis Factor InhibitorsClinical DermatologyInflammatory Rheumatic DiseasePharmacotherapyActive Psoriatic ArthritisDermatologyPsoriatic ArthritisRheumatoid Arthritis